Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

For significant weight loss, Zepbound may be the better option. If you have Type 2 diabetes and are looking for a dual ...

Most U.S. patients are covered by health insurance and would likely pay less for the drugs. Novo and rival Eli Lilly, which makes the weight loss drug Zepbound, have filed a flurry of lawsuits against ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Eli Lilly is testing an experimental drug called orforglipron which ... However, some concerns remain about misuse, especially as pills can make it easier to take more than recommended. While side ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

Jim Cramer warned that if the housing market rally keeps going, it might lead to a sell-off if the Federal Reserve announces ...

The current state of weight-loss treatments is about to shift with the forthcoming availability of GLP-1 drugs in the ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...